Rugo, H.S.; Xu, B.; Dasgupta, A.; Kaushik, A.; Verret, W.; Singh, B.
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Previously Treated HR+/HER− mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials. Cancers 2025, 17, 1885.
https://doi.org/10.3390/cancers17111885
AMA Style
Rugo HS, Xu B, Dasgupta A, Kaushik A, Verret W, Singh B.
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Previously Treated HR+/HER− mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials. Cancers. 2025; 17(11):1885.
https://doi.org/10.3390/cancers17111885
Chicago/Turabian Style
Rugo, Hope S., Binghe Xu, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, and Barinder Singh.
2025. "A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Previously Treated HR+/HER− mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials" Cancers 17, no. 11: 1885.
https://doi.org/10.3390/cancers17111885
APA Style
Rugo, H. S., Xu, B., Dasgupta, A., Kaushik, A., Verret, W., & Singh, B.
(2025). A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Previously Treated HR+/HER− mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials. Cancers, 17(11), 1885.
https://doi.org/10.3390/cancers17111885
